Drug Trial Radar · NCT01641367
A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
Last checked: Nov 20, 2026Latest source record: Mar 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
545
Actual
Start
Feb 22, 2013
Primary completion
Nov 23, 2016
Study completion Dec 31, 2018
Sponsor
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
- Sponsor type
- Research network
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID); AbbVie; Gilead Sciences; Janssen Pharmaceuticals; Merck Sharp & Dohme LLC; Dimagi Inc.
- First posted
- Jul 16, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study was done to: * test a strategy of using a resistance test to choose anti-HIV drugs * see how well combinations of new anti-HIV drugs work to lower HIV infection * see if taking new anti-HIV drugs together is safe and tolerable * see if text messages improve people's anti-HIV drug-taking behavior (only at sites participating in the adherence study) * in people taking certain combinations of anti-HIV drugs with an anti-TB drug, compare how these drugs act in the body * to see how people do after they stop having frequent clinic visits as part of a research study
Conditions
- HIV-1 Infection
Interventions
DarunavirDrug
Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \[200 mg per day\])
EtravirineDrug
Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
Emtricitabine/tenofovir disoproxil fumarateDrug
Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
RaltegravirDrug
Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)Drug
LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableDrug
For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
SOC adherence versus SOC+CPI adherenceOther
* not participating in the adherence randomization; OR * randomized to SOC adherence; OR * randomized to SOC+CPI adherence.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 WeeksTime frame: 48 weeks after the date of entry
Locations
19 sites in 10 countries. Site status is shown where the registry gives one.
Instituto de Pesquisa Clinica Evandro Chagas (12101)
Rio de Janeiro, Brazil
Hospital Nossa Senhora da Conceicao CRS (12201)
Porto Alegre, Rio Grande do Sul, Brazil
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS
Port-au-Prince, Haiti
Les Centres GHESKIO CRS (30022)
Port-au-Prince, Bicentaire, Haiti
BJ Medical College CRS (31441)
Pune, Maharashtra, India
Chennai Antiviral Research and Treatment (CART) CRS (11701)
Chennai, Taramani, India
AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601)
Eldoret, Kenya
Kenya Medical Research Institute/Center for Disease Control (KEMRI/CDC) CRS (31460)
Kisumu, Kenya
Malawi CRS (12001)
Lilongwe, Malawi
Barranco CRS (11301)
Lima, Peru
San Miguel CRS (11302)
San Miguel, Lima region, Peru
Durban Adult HIV CRS (11201)
Durban, South Africa
Soweto ACTG CRS (12301)
Johannesburg, South Africa
University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101)
Johannesburg, Gauteng, South Africa
Family Clinical Research Unit (FAM-CUR) CRS (8950)
Cape Town, West Cape, South Africa
31784 Chiang Mai University HIV Treatment CRS
Chiang Mai, Thailand
31802 Thai Red Cross AIDS Research Centre (TRC-ARC) CRS
Bangkok, Patumwan, Thailand
JCRC CRS
Kampala, Uganda
UZ-Parirenyatwa CRS (30313)
Harare, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.